Long-Term GLP-1 Treatment: Genetics, Nutrition, Muscle Preservation and Weight Maintenance
Last updated: November 2026 | Evidence review GLP-1 medications have transformed the management of obesity and metabolic disease. Medicines such as semaglutide and tirzepatide can produce substantial weight loss, improve several cardiometabolic risk factors and, in appropriate patients, provide benefits that extend beyond the number on the weighing scale. However, achieving weight loss is only part of the treatment journey. Other important questions emerge as treatment progresses: Why do some people lose substantially more weight than others taking the same medication? Can genetics help explain differences in medication response and side effects? How can nutritional deficiencies and muscle loss be prevented? Should patients continue treatment indefinitely after reaching their target weight? Can a lower maintenance dose preserve weight-loss benefits? What happens when someone reduces, stops or changes their medication? These questions should not be considered separate...